Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RBP4 | P02753 | 1/20 | 0.61 |
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1088005 | 0.89 | L3MBTL1 (0.69) | RBP4GPR119L3MBTL1POLB | |
| SCHEMBL406827 | 0.82 | GPR119 (0.62) | RBP4GPR119POLBUSP30 | |
| SCHEMBL31388218 | 0.81 | GPR119 (0.55) | RBP4GPR119POLBUSP30 | |
| SCHEMBL13128806 | 0.81 | GPR119 (0.56) | GPR119 | |
| SCHEMBL13128802 | 0.81 | L3MBTL1 (0.60) | RBP4L3MBTL1EPHX2 | |
| SCHEMBL13591117 | 0.80 | GPR119 (0.60) | GPR119POLBUSP30 | |
| SCHEMBL13391117 | 0.80 | GPR119 (0.60) | GPR119POLBUSP30 | |
| SCHEMBL29749275 | 0.80 | GPR119 (0.62) | RBP4GPR119EPHX2 | |
| SCHEMBL1087898 | 0.80 | GPR119 (0.62) | RBP4GPR119EPHX2 | |
| SCHEMBL8063381 | 0.79 | USP30 (0.68) | GPR119L3MBTL1POLBEPHX2USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100249098-A1 | OXYPIPERIDINE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION | 2010-09-30 | — | — | US | disclosed |
| WO-2009045313-A2 | OXYPIPERIDINE DERIVATIVES AS HISTAMINE RECEPTOR ANTAGONISTS | SCHERING CORPORATION (US) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249098-A1 | OXYPIPERIDINE DERIVATIVES AND METHODS OF USE THEREOF | OPRK1, GPR119, OPRD1 | RBP4 640/4885GPR119 2/4885L3MBTL1 2612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.